Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant vs Fulvestrant + CDK4/6i in ER+/HER2- Advanced Breast Cancer
NCT06065748Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2023
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Dec 2023; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06065748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065748.